Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                IVD Regulatory Assistance

IVD Regulatory Assistance

                        Clinical Laboratory Improvement Amendments (CLIA)
          CLIA Categorizations
          CLIA Waiver by Application
          Public Databases
          Overview of IVD Regulation Home
          Medical Devices
          Device Advice: Comprehensive Regulatory Assistance
          IVD Regulatory Assistance
          Good Clinical Practice (GCP) Requirements for Data Submitted from Clinical Investigations for In Vitro Diagnostic (IVD) Device Premarket SubmissionsIVD Regulatory Assistance Good Clinical Practice (GCP) Requirements for Data Submitted from Clinical Investigations for In Vitro Diagnostic (IVD) Device Premarket Submissions
  
  	
    Share
    Post
    Linkedin

    Email
    PrintThe FDA has established human subject protection regulations addressing requirements for informed consent and Institutional Review Board (IRB) review that apply to **all** clinical investigations of devices involving human subjects, including deidentified human specimens.

Investigations of medical devices involving human specimens, including deidentified human specimens, are clinical investigations under the FDA’s regulations, as clarified in the FDA’s 2006 guidance, Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable, and in the final rule entitled Human Subject Protection; Acceptance of Data from Clinical Investigations for Medical Devices (see the *FDA’s response to Comment 14* in the final rule 83 FR 7366).

Informed Consent Requirements

Informed consent requirements further both safety and ethical considerations by allowing potential subjects to consider both the physical and privacy risks they face if they agree to participate in a clinical trial. The FDA believes it is possible in certain circumstances for IVD device investigations to be conducted using leftover specimens, which are remnants of specimens collected for routine clinical care or analysis that would otherwise have been discarded, that were obtained without informed consent while still protecting the human subjects who are the source of such specimens. Thus, the FDA intends to exercise enforcement discretion with regard to the requirement for informed consent under the circumstances described in the FDA’s guidance, Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable.

However, this enforcement discretion does **not** apply to other good clinical practice (GCP) requirements, including IRB requirements under 21 CFR part 56. GCP includes review and approval by an IRB before initiating an investigation and continuing IRB review of ongoing investigations. The application of GCP helps to ensure the protections of the rights, safety, and welfare of human subjects and the quality and integrity of data from investigations using human specimens. IRB review is critical for protection of human subjects, particularly in regard to privacy and confidentiality, and the potential for use of information from the investigation for clinical patient management.

Data from Investigations Conducted Inside or Outside of the United States

The FDA's decisions are based on scientifically valid and ethically derived data. Conformance with GCP is one way to help ensure clinical data are credible, accurate, and ethically procured.

Premarket submissions supported by data from clinical investigations, including investigations involving human specimens, conducted **in the United States** require a statement of compliance with the GCP specified in 21 CFR parts 50, 56, and 812; or if the investigation was not conducted in compliance with those regulations, a brief statement of the reason for the noncompliance.

For premarket submissions supported by data from clinical investigations, including investigations involving human specimens, conducted **outside of the United States**, the submission must include information on conformance with GCP. If any such clinical investigation was not conducted in accordance with GCP, the submission must include either a waiver request or a brief statement of the reason for not conducting the investigation in accordance with GCP, and a description of steps taken to ensure that the data and results are credible and accurate and that the rights, safety, and well-being of subjects have been adequately protected. For additional information, please refer to 21 CFR 812.28 and Acceptance of Clinical Data to Support Medical Device Applications and Submissions: Frequently Asked Questions guidance.

                                                                                  Content current as of:
      09/27/2021
              
              
Regulated Product(s)
		 Medical DevicesIVD Regulatory Assistance

          
                        Clinical Laboratory Improvement Amendments (CLIA)
          CLIA Categorizations
          CLIA Waiver by Application
          Public Databases
          Overview of IVD Regulation
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop